Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019

Ali Bukhari; Jonathan Siglin; Forat Lutfi; Ankit J. Kansagra; Jean Yared; Aaron P. Rapoport; Saurabh Dahiya

doi:10.1016/j.critrevonc.2020.103007

Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019

Ali Bukhari, Jonathan Siglin, Forat Lutfi, Ankit J. Kansagra, Jean Yared, Aaron P. Rapoport, Saurabh Dahiya

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the field of hematologic malignancies and are potentially curative in patients with previously limited options. This review highlights key abstracts focusing on clinical studies in CAR-T therapy in leukemia and lymphoma presented at the 61 st annual meeting of the American Society of Hematology (December 2019, Orlando, FL). Selected studies discuss data on novel CAR-T constructs aimed at enhancing efficacy and durability of responses, improving toxicity mitigation strategies, challenging clinical scenarios in routine clinical practice for standard of care CAR-T therapy (role of bridging therapy, CNS involvement, and quality of life studies), and new technologies aiming to decrease production time to minimize delay in definitive therapy, all within the rapidly-evolving cellular immunotherapy landscape.

Original language	English (US)
Article number	103007
Journal	Critical Reviews in Oncology/Hematology
Volume	152
DOIs	https://doi.org/10.1016/j.critrevonc.2020.103007
State	Published - Aug 2020
Externally published	Yes

Keywords

Chimeric antigen receptor T-cell therapy
Cytokine release syndrome
Leukemia
Lymphoma
Neurotoxicity

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.critrevonc.2020.103007

Cite this

@article{3b6871f429f64066bb401d3c615eab2d,

title = "Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019",

abstract = "Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the field of hematologic malignancies and are potentially curative in patients with previously limited options. This review highlights key abstracts focusing on clinical studies in CAR-T therapy in leukemia and lymphoma presented at the 61 st annual meeting of the American Society of Hematology (December 2019, Orlando, FL). Selected studies discuss data on novel CAR-T constructs aimed at enhancing efficacy and durability of responses, improving toxicity mitigation strategies, challenging clinical scenarios in routine clinical practice for standard of care CAR-T therapy (role of bridging therapy, CNS involvement, and quality of life studies), and new technologies aiming to decrease production time to minimize delay in definitive therapy, all within the rapidly-evolving cellular immunotherapy landscape.",

keywords = "Chimeric antigen receptor T-cell therapy, Cytokine release syndrome, Leukemia, Lymphoma, Neurotoxicity",

author = "Ali Bukhari and Jonathan Siglin and Forat Lutfi and Kansagra, {Ankit J.} and Jean Yared and Rapoport, {Aaron P.} and Saurabh Dahiya",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier B.V.",

year = "2020",

month = aug,

doi = "10.1016/j.critrevonc.2020.103007",

language = "English (US)",

volume = "152",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019

AU - Bukhari, Ali

AU - Siglin, Jonathan

AU - Lutfi, Forat

AU - Kansagra, Ankit J.

AU - Yared, Jean

AU - Rapoport, Aaron P.

AU - Dahiya, Saurabh

PY - 2020/8

Y1 - 2020/8

N2 - Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the field of hematologic malignancies and are potentially curative in patients with previously limited options. This review highlights key abstracts focusing on clinical studies in CAR-T therapy in leukemia and lymphoma presented at the 61 st annual meeting of the American Society of Hematology (December 2019, Orlando, FL). Selected studies discuss data on novel CAR-T constructs aimed at enhancing efficacy and durability of responses, improving toxicity mitigation strategies, challenging clinical scenarios in routine clinical practice for standard of care CAR-T therapy (role of bridging therapy, CNS involvement, and quality of life studies), and new technologies aiming to decrease production time to minimize delay in definitive therapy, all within the rapidly-evolving cellular immunotherapy landscape.

AB - Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the field of hematologic malignancies and are potentially curative in patients with previously limited options. This review highlights key abstracts focusing on clinical studies in CAR-T therapy in leukemia and lymphoma presented at the 61 st annual meeting of the American Society of Hematology (December 2019, Orlando, FL). Selected studies discuss data on novel CAR-T constructs aimed at enhancing efficacy and durability of responses, improving toxicity mitigation strategies, challenging clinical scenarios in routine clinical practice for standard of care CAR-T therapy (role of bridging therapy, CNS involvement, and quality of life studies), and new technologies aiming to decrease production time to minimize delay in definitive therapy, all within the rapidly-evolving cellular immunotherapy landscape.

KW - Chimeric antigen receptor T-cell therapy

KW - Cytokine release syndrome

KW - Leukemia

KW - Lymphoma

KW - Neurotoxicity

UR - http://www.scopus.com/inward/record.url?scp=85085766490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085766490&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2020.103007

DO - 10.1016/j.critrevonc.2020.103007

M3 - Article

C2 - 32505824

AN - SCOPUS:85085766490

SN - 1040-8428

VL - 152

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 103007

ER -

Updates in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Lymphoma and Leukemia from the Annual Meeting of American Society of Hematology 2019

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this